impact of european legislation on indian api manufacturers

Nandkumar Chodankar (Ph D)

Sekhsaria Chemicals Ltd.

Mumbai, India

Impact of European Legislation on

Indian API Manufacturers

9th APIC/CEFIC

European Conference on Active Pharmaceutical Ingredients

10th October2006 (09.00-09.45)

10th Oct. 2006 Nandkumar Chodankar 2/28

European Legislation Requirements 2-8

Evolution of Indian Pharmaceutical Industry 9

Historical Background 10-14

Journey –DMF-COS- CTD 14

Current Scenario 15

Impact of CTD format on document submission 16

Impact of ICH Q 7 Guidelines 17

Continuous Improvement 18-20

Impact of Customer audits on the API Manufacturers

20

Impact of Increase in the audit frequency 22

Impact due to other factors 25

Summary 26


European New Legislation

• The pharmaceutical manufacturer is responsible for ensuring that the APIs have been manufactured in accordance with the EU Guidelines to Good Manufacturing Practice for Active Substances, Volume 4, Part II.

• After 17th December 2005, pharmaceutical manufacturer’s QP certifies by his or her signature to the register for release of medicinal products that also the API has been manufactured in accordance with GMP

• This means that after that date the signature of the QP implies a greater responsibility. No separate signature is required in the register to certify that APIs have been manufactured in accordance with GMP.


Document to substantiate that APIs have been manufactured in accordance to GMP

• The pharmaceutical manufacturer must have evidence of appropriate audit being performed on all its API manufacturers (in respect of manufacturing, packaging, repackaging, mixing, labeling, re-labeling, and supplementary labeling). Audit reports will become an issue for future inspections at the premises of pharmaceutical manufacturers.


Are third party inspection reports acceptable?

• Most of the EU accepts third party inspections reports with following conditions, that:• The auditor is a QP• The auditor is independent of the company to be audited.• The auditor is acquainted with the rules of the governing

medicinal products in the European Union, Volume 4, Part II

• The audit report has been reviewed by the pharmaceutical manufacturer

• The audit report is adequate .• Third party audit report must be in detail not just a

summary.


Today’s Situation• From 17th December 2005 onwards the medicinal

products of an API manufacturer who is not audited are quarantined on inspection until the API manufacturer has been audited.• Exception to the rule is there are some medicinal

products that are not comprised by the rules on APIs.• Medicinal products dispensed by a special

compassionate-use- permit in EU (Denmark)• Medicinal products prepared in accordance with a

magisterial formula• Medicinal products for clinical studies for which a

marketing authorization has not been granted GMP Requirement for API questions & Answers) http;//www.dkma.dk/1024/visUKLSArtikel.asp


Definition of API Manufacturer

• An API manufacturer is defined in Executive Order No. 1242 of 12 December 2005, which briefly states that the API manufacturer is:• The manufacturer of API • The company in charge of packaging the APIs• The company in charge of repackaging / un-

packaging, mixing the APIs• The company in charge of labeling or relabeling

or providing supplementary labels for API.


Are Regular Inspections in the offing?

• As a general rule, API manufacturers will not be inspected at regular intervals unless the manufacture concerned requires an authorization pursuant to EU Medicinal Act

• API manufacturer who wish to receive GMP certificate must request an authority inspection.

Evolution of Indian Pharmaceutical Industry


Indian Pharma Industry: Historical Background

1950-60 Small Indian Pharmaceutical Industry

Drug product Importation, Repackaging & Distribution

1960-70 Multinational Companies (MNCs) started manufacturing drug product with prevailing GMP with limited API manufacturing (last step)

1970-80 Government of India took initiative to put up API manufacturing facility for potent antibiotics & other drugs, vitamins etc.

Indian entrepreneurs were encouraged to start API & drug product manufacturing to meet the domestic demand & to save foreign exchange


Indian Pharma Industry: Historical Background1980-1990

The Indian Industry dominated.Took part in Trade Exhibitions.Exports of APIs to Hamburg and Italy and Drug

products to non-regulated countries (neutral pack) European and American Generic Manufacturers

started taking interest DMF for API submission to various AuthoritiesInspections from Health Authorities startedMNC’s market share reversed (70:30 to 30:70)Many more Small & Medium scale Drug Product

manufacturing industry started


Indian Pharma Industry: Historical Background1990-2000

Started Research & Development & entered into Biotechnology field.

Inspections from US FDA, MHRA, EDQM & other Regulators increased many folds.

Latest drug products become easily available at substantially low prices

Inspections of Formulation plants from MHRA, US FDA, IMBA, WHO and other Authorities opened the door for the Global Pharma Market

Continuous Improvement in the application of GMP and Quality Management


Approximately 11,000 registered units, engaged in the manufacture of drug substances and drug products. Among these around 300 are Large scale

More than 300 units have approval from International

Agencies

All units licensed for export (300) are inspected by

domestic Regulatory (Central & State) team, for

WHO certification

150- have received Approvals from: MHRA, TGA, etc.

65 are US FDA Inspected & accepted.

Indian Historical Background


Journey: DMF to EDMF- COS –CTD Formats

UK companies took the lead and their Quality Assurance personnel started investing their time in Indian companies. Grabbing of opportunity: Indians were quick to learn and grab the opportunity.Introduction of COS and its declaration that the APIs are manufactured under GMP, Introduction of ICH Guidelines and their implementation:.The CTD format for DMF submission.


Current scenario: DMFs, COSs, Dossiers and ANDAs

DMF Filing by Indians: Largest number of DMFs & COSs from Indian Companies

About 132 ANDA in Partnerships have been submitted with US Generic companies. Similarly Dossiers have been submitted

A few have signed partnerships.

The acquisitions of pharmaceutical industries by Indians and vice versa.

Indian Generic Products available at Indian cost with

International standard for all Regulated Markets


The impact of CTD Formats for Document submission

• The new legislation such as improved documentation/CTD is a positive move for all involved as it is moving to one common standard of documents and ultimately material and pharmacopoeia standards which has a very positive impact on the ability of companies to produce good documentation and quality product. Indians have taken a lead in this field.


The Impact: ICH Q 7 requirements for GMP Manufacturing

Implementation of ICH Q7 A guideline for manufacturing API and Intermediates.

Training of the staff to understand and to follow the requirements of the ICH guidelines

Realigning of the facilities to meet GMP & environmental requirements

Separation of the Final API purification step from the other synthetic steps, and manufacture it with precisely as per the ICH Q7 Requirements

Product isolation at each stage of manufacturing in a controlled environment.

Critical unit operations like Drying, Milling, Packaging, Labeling, etc., in controlled environment.


Continuous Improvement (At What Cost?)

Quality Management

Personnel selection and their education, apparels, etc.

Equipment design, finishes

Documentation & Records

Material Management & Sampling

Production & Process control, Contamination control, Blending to make large batch size & blending of Tailings

Laboratory Control

Stability monitoring & Storage conditions

Expiry and Retest Period (Reprocessed Material?)


Continuous Improvement (At What Cost?)Qualification (URS, DQ, IQ, OQ, PQ)

Calibrations

Validations Process Validation (Prospective, retrospective,

concurrent) Analytical method validation, Cleaning process and analytical method validations

OOS, OOT,

Change Control,

Annual reports,

Reprocessing, Recovery, Reworking

Returns and Complaint handling, etc. Agents, brokers, traders, distributors, re-packers & re-labelers


Impact of Increase in the audit frequency

Positive Impact Other side of the impact

Number of Audit frequency has increased

The overall cost and time required has increased.

Requirement of the number of QA & other staff personnel has increased

Time spent from personnel with the auditors to explain the systems, processes, from individual department has increased, at the cost of routine work

Different auditors have different views and interpretation of the ICH guidelines leading to confusion (Comparison)




Audits have increased the awareness of GMP requirement among the staffs (Training)

Though this is good way of training, is not recorded as training in the training documentation

Observation, lead to discussions & debates during and after audits for finding solutions. This is Good as a training aid.

These kind of discussions lead to confusion and the end result is sometime negative Need to Edit the Observation

Preparation of audit minutes for management awareness, Review of the audit reports.

Increase in the time required for these activities, the paper work and documentation (to prepare suitable answers) etc.




Preparation of the answers and implementing corrective measures for every audit. (Continuous improvement)

Time required for review and approval of corrective action from the higher management has increased.

Changes suggested in SOPs during audits to meet ICH guidelines

Sometimes such changes are not practical and may not be possible to implement.

Overall commitment for corrective measures

(Continuous Compliance preparedness)

May not be possible to implement as planned due to circumstances and thus creates a bad impression in the mind of the staff




Audit reports are received after long time, sometimes after two months. (Auditors have too many Audits to conduct and prepare reports, sometimes may miss vital details or context provided )

This delay indirectly reduces the importance of the auditors concern. The audit observation should be made available immediately to have greater effect.


Impact due to other factors

• Overall documentation / Expectation and Paper work has increased.

• Analytical work has increased, especially Validation of every method that is used.

• QC, QA, Documentation staff has increased almost by two folds

• Customer request for impurity reference standards has increased.


Summary

• European Legislation is showing a positive effect on the Indian API manufacturers with long term benefits to the end customer

• Among 11,000 Registered units (India), only 300 are large and medium scale Manufacturing units and have almost 70% market share

• EDQM and US FDA inspections have brought in a change in the “Mind Set”

• European customers have started Auditing the API Manufacturing Plants, which is leading to up-gradation of the facilities, documentation and Quality Assurance Systems

• Domestic CGPM Guidelines “Schedule M” (almost equivalent to ICH Q7A) are being enforced on all manufacturing plants.

• To meet CGMP New API Manufacturing plants are being installed using ISPE & ICH Guidelines.


• I will like to thank the following individuals for making this presentation possible;

• Laurie Cook

• Lalit Sharma


To Vacuum

Impact of European Legislation on Indian API manufacturers

SEKHSARIA

Pump

Receiver

Multi Mill

To Recovery

Crystallization Reactor

Blender

Sifter

Mother LiquorTank

SEKHSARIA

SEKHSARIA

UTILITY

UTILITY

UTILITY

Multi Mill

Blender

MillDryer Packaging

Sifter

Centrifuge

Dissolution Reactor

impact of european legislation on indian api manufacturers

Documents

manufacturer of api

governing medicinal

release of medicinal

eu denmarkmedicinal

audit reports

api questions answers

party audit report

charge of labeling